We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible....

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners Funds to be used to continue...

Life sciences leader to advance Mediar’s novel platform for fibrosis

Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform Rome Therapeutics...

Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look. Vanqua Bio Closes $85...

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Disease

Studying inhaled NTX-1175, A First-In-Class, Charged Sodium Channel Blocker Phase 2a Study Expected to Enroll 40 Chronic Cough Patients

Gene editing analysis company SeQure Dx said on Tuesday that it has closed a $17.5 million Series A funding round

Lyndra Therapeutics Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other

Lyndra Therapeutics Completes $60.5 Million Series C Financing

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment...

Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie.

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-34

Investors back a $110M reboot effort. Source: EndPoints News Next week, Affinia Therapeutics will present four new abstracts at the...

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia

ZP-3601 - Its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021) LYON,...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed...

Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV)

Proceeds Support Advancement of VERVE-101 toward Clinical Initiation in 2022 CAMBRIDGE, Mass. — January 19, 2021 — Verve Therapeutics, a...

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round...